STOCKWATCH: In biotech poker pairs can beat a full house
This article was originally published in Scrip
Executive Summary
Amid ‘lackluster’ quarterly results, there has been a lot of talk about rotation, which is investor slang for cashing out and looking for the next big opportunity. When the biotech sector (scripintelligence.com, 8 October 2013) and, more recently to a lesser extent, the pharmaceutical sector, perform well against the general market, there is always the worry that investors will take profits and move on. This has become much more acute in the past few weeks.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.